Protagonist Therapeutics, Inc. (PTGX)
| Market Cap | 1.28B |
| Revenue (ttm) | 31.17M |
| Net Income (ttm) | -70.07M |
| Shares Out | 43.95M |
| EPS (ttm) | -1.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 10 |
| Last Price | $28.67 |
| Previous Close | $29.18 |
| Change ($) | -0.51 |
| Change (%) | -1.75% |
| Day's Open | 28.95 |
| Day's Range | 28.07 - 30.09 |
| Day's Volume | 78,489 |
| 52-Week Range | 13.54 - 32.10 |
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.26% and 65.04%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
NEWARK, Calif., May 4, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or the "Company") today reported financial results for the first quarter of 2021 ended March 31, 2021 a...
NEWARK, Calif., May 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on April 30, 2021, it issued an inducement award to Ramesh Bhatt, the Company's recently hir...
NEWARK, Calif., April 27, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (Nasdaq: PTGX), today announced the completion of enrollment for the Company's Phase 2 stud...
NEWARK, Calif., March 22, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") announced today that the Division of Nonmalignant Hematology at the U.S. Food and ...
Protagonist Therapeutics (PTGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the...
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -2.13% and 67.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
NEWARK, Calif., March 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (Nasdaq: PTGX) today reported financial results and provided a corporate update for the fou...
NEWARK, Calif., March 3, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), today announced it will host a conference call and webcast on Wednesday, March 10 at 4:30 pm ET/1:30 pm PT to...
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEWARK, Calif., Feb. 26, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported that on February 26, 2021, it issued an inducement award to Jami Taylor, the Company's recently...
NEWARK, Calif., Jan. 29, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 29, 2021, it issued an inducement award to Paula O'Connor, M.D., the Company's r...
NEWARK, Calif., Jan. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the 39th An...
Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.
NEWARK, Calif., Dec. 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first subject has been dosed in a Phase 1 study of PN-235 (also referenced as JNJ-7724...
NEWARK, Calif., Dec. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwrit...
NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwrit...
NEWARK, Calif., Dec. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offe...
NEWARK, Calif., Dec. 7, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the results of a large-scale analysis of real world treatment patterns for polycythemia vera, de...
NEWARK, Calif., Dec. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced additional updated results from the ongoing Phase 2 study of PTG-300 in patients with polycythem...
NEWARK, Calif., Nov. 30, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) and Co...
NEWARK, Calif., Nov. 25, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fire...
NEWARK, Calif., Nov. 11, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fires...
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 65.57% and 245.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...
NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported its financial results for the third quarter ended September 30, 2020, and provided a corporate u...
NEWARK, Calif., Nov. 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced the acceptance of one oral and four poster presentations at the American Society for Hematology...
NEWARK, Calif., Oct. 29, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that two additional oral peptide IL-23 receptor antagonist candidates from its collaboration ag...
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEWARK, Calif., Oct. 21, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the European Medicines Agency (EMA) has granted orphan drug designation for PTG-300 in the...
NEWARK, Calif., Sept. 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fire...
NEWARK, Calif., Sept. 15, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.
NEWARK, Calif., Sept. 10, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.
NEWARK, Calif., Sept. 2, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.
NEWARK, Calif., Aug. 13, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc.
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pharmaceutical stocks dipped by a single-digit percentage in the first six months of 2020, trailing their biotech brethren. Still, there are standout companies in the group.
Why Protagonist Should Be On Your Radar After Latest Trial Update
The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.
NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-3...
NEWARK, Calif., June 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fires...
Protagonist Therapeutics: Robust Polycythemia Vera Data Is Just The Beginning
NEWARK, Calif., June 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-t...
NEWARK, Calif., May 28, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at two upcoming...
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q1 2020 Results - Earnings Call Transcript
Here's what's behind their impressive market performances.
Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.
Why is Protagonist Therapeutics (PTGX) Soaring 90% Today?
zacks.com zacks.com/ultimate
The company is set to start a pivotal study for one of its lead pipeline candidates.
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript
Protagonist Therapeutics, Inc. (PTGX) CEO Dinesh Patel on Q4 2019 Results - Earnings Call Transcript
About PTGX
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. It is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PTG-200, an oral, interleukin-23 receptor specific antagonist peptide, which is in phase II clinical trial for the treatment of moderate-to-severe Crohn's ... [Read more...]
| Industry Biotechnology | IPO Date Aug 11, 2016 |
| Stock Exchange NASDAQ | Ticker Symbol PTGX |
Financial Performance
In 2020, PTGX's revenue was $28.63 million, an increase of 12,293.07% compared to the previous year's $231,000. Losses were -$66.15 million, -14.30% less than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for PTGX stock is "Buy." The 12-month stock price forecast is 37.40, which is an increase of 30.45% from the latest price.